We at the ACR acknowledge all ACR, ARP and Rheumatology Research Foundation volunteers whose committee terms are ending in November. Thank you for your valuable time and efforts toward advancing rheumatology during a challenging time. ACR: Board of Directors Kenneth G. Saag, MD, MSc; ACR President Barbara Slusher, MSW, PA-C; ARP President Anne R. Bass,…
The 2022 Rheumatic Disease Report Card found that many states can improve access to care, affordability & activity for their residents living with rheumatic diseases.
In recent months, the ISC has engaged with payers to reduce administrative burden on practices and continues to advocate to the CMS for the use of complex administration codes for biologics.
The ACR and a new Access to Reproductive Health Care Task Force are working to ensure patients with rheumatic disease—particularly women—have access to the medications and treatments they need, including methotrexate, and that rheumatology providers are able to maintain trusting relationships with and advise their patients on all matters relevant to the management of their rheumatic diseases.
The ACR’s resolution addressing inappropriate Medicare Administrative Contractor policy processes was adopted, and two co-led resolutions on ARPA-H funding and saline shortages also passed the policy-making body.
After two years of special virtual sessions, the AMA House of Delegates will reconvene in person June 10–15. ACR representatives will focus on Medicare physician payment system reform, national drug shortages, funding the new Advanced Research Projects Agency for Health and more.
More than 70 rheumatologists and rheumatology health professionals convened in Washington, D.C., to advocate on behalf of legislation that would reduce patients’ out-of-pocket drug costs and help grow America’s healthcare workforce.
The meetings will focus on legislation affecting rheumatology, including bills on graduate medical education and use of copay assistance funds.
At a recent ACR town hall, four rheumatologists shared strategies that have helped them recruit new physicians amid a significant nationwide rheumatology workforce shortage.
The ISC has worked with CVS Caremark to revisit changes to its prior authorization forms that would have increased the administrative burden on practices, and patients with Blue Cross Blue Shield of South Carolina may not have to worry about switching to a self-administered biologic.